adegramotide adegramotide adegramotide (dsp-7888) is an experimental drug intended for treatment of glioblastoma multiforme. it is a peptide vaccine and, as of 2017, in phase ii clinical trials. adegramotidelegal statuslegal status experimental identifiers iupac name l-tryptophyl-l-alanyl-l-prolyl-l-valyl-l-leucyl-l-alpha-aspartyl-l-phenylalanyl-l-alanyl-l-prolyl-l-prolyl-glycyl-l-alanyl-l-seryl-l-alanyl-l-tyrosyl-glycyl-l-seryl-l-leucine cas number1252802-98-4pubchem cid121488164chemspider59651405unii4xq7w02eq0keggd11057chemical and physical dataformulac87h123n19o24molar mass1819.050 g·mol−13d model (jsmol)interactive image smiles c(c(=o)n(co)c(=o)n(c)c(=o)n(cc1=cc=c(c=c1)o)c(=o)ncc(=o)n(co)c(=o)n(cc(c)c)c(=o)o)nc(=o)cnc(=o)2cccn2c(=o)3cccn3c(=o)(c)nc(=o)(cc4=cc=cc=c4)nc(=o)(cc(=o)o)nc(=o)(cc(c)c)nc(=o)(c(c)c)nc(=o)5cccn5c(=o)(c)nc(=o)(cc6=cnc7=cc=cc=c76)n inchi inchi=inchi=1s/c87h123n19o24/c1-44(2)33-58(100-83(125)71(46(5)6)103-82(124)66-24-17-30-104(66)84(126)49(9)94-74(116)56(88)37-53-39-89-57-22-15-14-21-55(53)57)77(119)99-61(38-70(112)113)78(120)98-60(35-51-19-12-11-13-20-51)76(118)95-50(10)85(127)106-32-18-25-67(106)86(128)105-31-16-23-65(105)81(123)91-40-68(110)92-47(7)72(114)102-64(43-108)79(121)93-48(8)73(115)97-59(36-52-26-28-54(109)29-27-52)75(117)90-41-69(111)96-63(42-107)80(122)101-62(87(129)130)34-45(3)4/h11-15,19-22,26-29,39,44-50,56,58-67,71,89,107-109h,16-18,23-25,30-38,40-43,88h2,1-10h3,(h,90,117)(h,91,123)(h,92,110)(h,93,121)(h,94,116)(h,95,118)(h,96,111)(h,97,115)(h,98,120)(h,99,119)(h,100,125)(h,101,122)(h,102,114)(h,103,124)(h,112,113)(h,129,130)/t47-,48-,49-,50-,56-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,71-/m0/s1key:qmukfzmayhsadk-mzddnwlqsa-n